Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Operating Leases came in at $282.0 million in Q2 2026, down 4.73% YoY from $296.0 million in Q2 2025, and up 0.71% on a QoQ basis from $280.0 million in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 9 years of Operating Leases data on file, last reported at $282.0 million in Q2 2026.
- Quarterly Operating Leases fell 4.73% year-over-year to $282.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $282.0 million (down 4.73% YoY) and the FY2025 annual result came in at $288.0 million, down 24.8% from the prior year.
- Operating Leases climbed to $282.0 million in Q2 2026, from $280.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $442.0 million in Q4 2022 to a low of $280.0 million in Q1 2026.
- A 5-year average of $330.8 million and a median of $310.0 million in 2023 frame the typical range for Operating Leases.
- The widest YoY moves for Operating Leases: up 5.34% in 2025, down 24.8% in 2025.
- Tracing TEVA's Operating Leases over 5 years: stood at $442.0 million in 2022, then declined by 5.66% to $417.0 million in 2023, then declined by 8.15% to $383.0 million in 2024, then retreated by 24.8% to $288.0 million in 2025, then slipped by 2.08% to $282.0 million in 2026.
- The last three Operating Leases figures came in at $282.0 million (Q2 2026), $280.0 million (Q1 2026), and $288.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 282.00 Mn |
| Mar 31, 2026 | 280.00 Mn |
| Dec 31, 2025 | 288.00 Mn |
| Sep 30, 2025 | 283.00 Mn |
| Jun 30, 2025 | 296.00 Mn |
| Mar 31, 2025 | 288.00 Mn |
| Dec 31, 2024 | 383.00 Mn |
| Sep 30, 2024 | 295.00 Mn |
| Jun 30, 2024 | 281.00 Mn |
| Mar 31, 2024 | 294.00 Mn |
| Dec 31, 2023 | 417.00 Mn |
| Sep 30, 2023 | 324.00 Mn |
| Jun 30, 2023 | 338.00 Mn |
| Mar 31, 2023 | 345.00 Mn |
| Dec 31, 2022 | 442.00 Mn |
| Sep 30, 2022 | 354.00 Mn |
| Jun 30, 2022 | 371.00 Mn |
| Mar 31, 2022 | 393.00 Mn |
| Dec 31, 2021 | 525.00 Mn |
| Sep 30, 2021 | 425.00 Mn |